Compare McKesson Corporation (MCK) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Marsh & McLennan Companies, Inc. — how do they compare? McKesson Corporation trades at $824.94 (market cap $97.35B), while Marsh & McLennan Companies, Inc. trades at $182.46 (market cap $87.77B). The key difference: McKesson Corporation and Marsh & McLennan Companies, Inc. are close in size by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| MCK | MRSH | |
|---|---|---|
Market Cap | $97.35B | $87.77B |
Sector | Health | Financials |
52-Week High | $995.69 | $211.21 |
52-Week Low | $659.01 | $157.32 |
Enterprise Value | $101.98B | $108.61B |
Dividend Yield | 0.39% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Marsh (MRSH) trades at $181.79, down slightly (-0.21%) on the day. The stock exhibits a bullish technical trend with strong moving average signals, while fundamentals are solid with consistent revenue growth to $26.98B in 2025 and a robust net income margin of 14.26%. Recent news highlights a 10% dividend increase to $0.99 per share and strategic partnerships expanding its advisory business. The company has beaten earnings estimates for the last three consecutive quarters.
The outlook for MRSH is positive, supported by earnings momentum and shareholder returns, though rising operating expenses and a premium valuation (P/E of 22.77) present near-term risks. Analyst consensus is a 'Hold' with a $203.75 price target, suggesting modest upside potential from current levels, but investor sentiment is tempered by cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
